Prescription Duloxetine Capsules Recalled for Nitrosamine Impurity
Breckenridge Pharmaceutical is recalling Duloxetine 30 mg capsules distributed nationwide due to a nitrosamine impurity above acceptable limits. Consumers should consult their doctor about their medication.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II FDA recall for a manufacturing deviation involving an impurity above the recommended limit. No illnesses or injuries have been reported, making this a theoretical risk-of-harm situation that qualifies as High severity per the rubric.
Plain-English summary
Breckenridge Pharmaceutical, Inc. is recalling Duloxetine Delayed-Release Capsules, USP, 30 mg (NDC 51991-747-10). The product is supplied in bottles of 1,000 capsules and was manufactured by Towa Pharmaceutical Europe, S.L., located in Martorelles, Barcelona, Spain.
The recall is due to a CGMP (good manufacturing practice) deviation. The deviation involves the presence of N-nitroso-duloxetine, a nitrosamine drug substance related impurity (NDSRI), at levels above the FDA's recommended interim limit.
The affected product (Lot 240909C, expiration date 03/31/2027) was distributed nationwide in the United States. Approximately 14,863 bottles are involved in this recall.
Consumers taking this medication should contact their pharmacist or healthcare provider for guidance regarding whether to continue using their current supply.
The recalled product
- Product
- DULOXETINE (DULOXETINE HYDROCHLORIDE)
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc.
- Category
- Drug — Antidepressant
- Hazard
- nitrosamine
- impurity
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 240909C
- Exp Date 03/31/2027
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DULOXETINE
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules 20 mg Recalled for Impurity
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above Limit
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above FDA Limit
FDA (Drugs) · 2026-05-13
- HighDuloxetine Capsules Recalled for N-Nitroso Impurity Exceeding FDA Limits
FDA (Drugs) · 2025-03-19
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27